Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity

Virology
Evelien M BunnikHanneke Schuitemaker

Abstract

Autologous HIV-1-specific neutralizing antibodies (NAbs) seem unable to inhibit viral replication as they rapidly select for neutralization escape variants. However, NAbs could potentially contribute indirectly to the control of HIV-1 if changes in the viral envelope coinciding with NAb escape would impair viral replication fitness. Here we analyzed the replication kinetics of HIV-1 isolated over the course of infection from five typical progressors, three of whom developed strong autologous neutralizing humoral immunity. Viral replication rate did not correlate with viral sensitivity to autologous serum neutralization or with envelope length or number of potential N-linked glycosylation sites in gp120, suggesting that the flexibility of the viral envelope allows escape from NAbs without the loss of viral fitness. Interestingly, the appearance of rapidly replicating viruses late in infection correlated with lower CD4(+) T-cell counts, suggesting that this viral characteristic may be positively selected when the availability of target cells becomes limiting.

References

Dec 1, 1989·AIDS·J A McKeatingR A Weiss
May 6, 1999·The Journal of Infectious Diseases·D CeciliaS Zolla-Pazner
Mar 20, 2003·Proceedings of the National Academy of Sciences of the United States of America·Douglas D RichmanChristos J Petropoulos
Mar 21, 2003·Nature·Xiping WeiGeorge M Shaw
Feb 11, 2004·Nature Medicine·A J LeslieP J R Goulder
Feb 18, 2004·Nature Medicine·Thomas C FriedrichDavid I Watkins
Jun 9, 2005·Reviews in Medical Virology·Tim van Opijnen, Ben Berkhout
May 10, 2006·The Journal of Experimental Medicine·Justin R BaileyJoel N Blankson
Mar 3, 2007·Journal of Virology·Christopher J MillerJoseph M McCune
Apr 6, 2007·Journal of Virology·E S GrayUNKNOWN CAPRISA 002 Study Team
Mar 8, 2008·Nature Protocols·Angélique B van 't WoutNeeltje A Kootstra
Jan 16, 2009·The Journal of Infectious Diseases·Manish SagarThomas C Quinn
Feb 23, 2010·The Journal of Infectious Diseases·Zelda EulerHanneke Schuitemaker

❮ Previous
Next ❯

Citations

Sep 25, 2010·The Journal of Infectious Diseases·Christian L BoutwellTodd M Allen
Sep 3, 2011·PloS One·Marlén M I Aasa-ChapmanÁine McKnight
Mar 25, 2011·Current Opinion in HIV and AIDS·Michael A LobritzEric J Arts
Aug 29, 2014·Journal of Virology·Jane C YaciukWilliam H Hildebrand
Nov 23, 2013·The Journal of Biological Chemistry·Anjali JoshiHimanshu Garg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.